Hospira 3Q09

3Q Revenues: $1.0 billion (+9%)

3Q Earnings: $116.2 million (+42%)

YTD Revenues: $2.8 billion (+4%)

YTD Earnings: $307.2 million (+42%)

Comments: In the quarter, Global Specialty Injectables revenue was $575.7 million (+24%). In the Americas, sales were $449.1 million (+32%). Asia Pacific sales were flat at $57.0 million. Revenue for Other Pharma (including contract manufacturing) was down 2% to $126.0 million in 3Q09. Global Specialty Injectables revenue YTD was $1.5 billion (+10%), with the Americas accounting for $1.2 billion (+17%) and Asia Pacific, $149.0 million (+4%).